ALT Quote, Financials, Valuation and Earnings

CorMedix, Inc. has a net margin of -105223.08% compared to Altimmune, Inc.'s net margin of 10.9%. Altimmune, Inc.'s return on equity of -52.59% beat CorMedix, Inc.'s return on equity of 67.96%.

Altimmune, Inc. has a consensus price target of $18.00, signalling upside risk potential of 439.73%. On the other hand CorMedix, Inc. has an analysts' consensus of $14.57 which suggests that it could grow by 106.69%. Given that Altimmune, Inc. has higher upside potential than CorMedix, Inc., analysts believe Altimmune, Inc. is more attractive than CorMedix, Inc..

Altimmune, Inc. has a beta of 0.343, which suggesting that the stock is 65.693% less volatile than S&P 500. In comparison CorMedix, Inc. has a beta of 1.406, suggesting its more volatile than the S&P 500 by 40.623%.

Altimmune, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CorMedix, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Altimmune, Inc. pays -- of its earnings as a dividend. CorMedix, Inc. pays out -- of its earnings as a dividend.

Altimmune, Inc. quarterly revenues are $26K, which are smaller than CorMedix, Inc. quarterly revenues of $128.6M. Altimmune, Inc.'s net income of -$27.4M is lower than CorMedix, Inc.'s net income of $14M. Notably, Altimmune, Inc.'s price-to-earnings ratio is -- while CorMedix, Inc.'s PE ratio is 3.57x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Altimmune, Inc. is 7,057.52x versus 1.83x for CorMedix, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly & Co. has a net margin of -105223.08% compared to Altimmune, Inc.'s net margin of 34.4%. Altimmune, Inc.'s return on equity of -52.59% beat Eli Lilly & Co.'s return on equity of 104.39%.

Altimmune, Inc. has a consensus price target of $18.00, signalling upside risk potential of 439.73%. On the other hand Eli Lilly & Co. has an analysts' consensus of $1,209.21 which suggests that it could grow by 29.25%. Given that Altimmune, Inc. has higher upside potential than Eli Lilly & Co., analysts believe Altimmune, Inc. is more attractive than Eli Lilly & Co..

Altimmune, Inc. has a beta of 0.343, which suggesting that the stock is 65.693% less volatile than S&P 500. In comparison Eli Lilly & Co. has a beta of 0.506, suggesting its less volatile than the S&P 500 by 49.45%.

Altimmune, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly & Co. offers a yield of 0.68% to investors and pays a quarterly dividend of $1.73 per share. Altimmune, Inc. pays -- of its earnings as a dividend. Eli Lilly & Co. pays out 26.14% of its earnings as a dividend. Eli Lilly & Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Altimmune, Inc. quarterly revenues are $26K, which are smaller than Eli Lilly & Co. quarterly revenues of $19.3B. Altimmune, Inc.'s net income of -$27.4M is lower than Eli Lilly & Co.'s net income of $6.6B. Notably, Altimmune, Inc.'s price-to-earnings ratio is -- while Eli Lilly & Co.'s PE ratio is 40.61x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Altimmune, Inc. is 7,057.52x versus 12.82x for Eli Lilly & Co.. Usually stocks with elevated PS ratios are considered overvalued.

Madrigal Pharmaceuticals, Inc. has a net margin of -105223.08% compared to Altimmune, Inc.'s net margin of -18.24%. Altimmune, Inc.'s return on equity of -52.59% beat Madrigal Pharmaceuticals, Inc.'s return on equity of -42.53%.

Altimmune, Inc. has a consensus price target of $18.00, signalling upside risk potential of 439.73%. On the other hand Madrigal Pharmaceuticals, Inc. has an analysts' consensus of $668.57 which suggests that it could grow by 22.25%. Given that Altimmune, Inc. has higher upside potential than Madrigal Pharmaceuticals, Inc., analysts believe Altimmune, Inc. is more attractive than Madrigal Pharmaceuticals, Inc..

Altimmune, Inc. has a beta of 0.343, which suggesting that the stock is 65.693% less volatile than S&P 500. In comparison Madrigal Pharmaceuticals, Inc. has a beta of -0.995, suggesting its less volatile than the S&P 500 by 199.535%.

Altimmune, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Madrigal Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Altimmune, Inc. pays -- of its earnings as a dividend. Madrigal Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Altimmune, Inc. quarterly revenues are $26K, which are smaller than Madrigal Pharmaceuticals, Inc. quarterly revenues of $321.1M. Altimmune, Inc.'s net income of -$27.4M is higher than Madrigal Pharmaceuticals, Inc.'s net income of -$58.6M. Notably, Altimmune, Inc.'s price-to-earnings ratio is -- while Madrigal Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Altimmune, Inc. is 7,057.52x versus 13.20x for Madrigal Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Viking Therapeutics, Inc. has a net margin of -105223.08% compared to Altimmune, Inc.'s net margin of --. Altimmune, Inc.'s return on equity of -52.59% beat Viking Therapeutics, Inc.'s return on equity of -46.41%.

Altimmune, Inc. has a consensus price target of $18.00, signalling upside risk potential of 439.73%. On the other hand Viking Therapeutics, Inc. has an analysts' consensus of $92.72 which suggests that it could grow by 166.44%. Given that Altimmune, Inc. has higher upside potential than Viking Therapeutics, Inc., analysts believe Altimmune, Inc. is more attractive than Viking Therapeutics, Inc..

Altimmune, Inc. has a beta of 0.343, which suggesting that the stock is 65.693% less volatile than S&P 500. In comparison Viking Therapeutics, Inc. has a beta of 0.833, suggesting its less volatile than the S&P 500 by 16.689%.

Altimmune, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Viking Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Altimmune, Inc. pays -- of its earnings as a dividend. Viking Therapeutics, Inc. pays out -- of its earnings as a dividend.

Altimmune, Inc. quarterly revenues are $26K, which are larger than Viking Therapeutics, Inc. quarterly revenues of --. Altimmune, Inc.'s net income of -$27.4M is higher than Viking Therapeutics, Inc.'s net income of -$157.7M. Notably, Altimmune, Inc.'s price-to-earnings ratio is -- while Viking Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Altimmune, Inc. is 7,057.52x versus -- for Viking Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.